Evidence-based analysis of modafinil, alprazolam, and amphetamine pharmacokinetics — including titration protocols, detection windows, half-life calculations, and vendor reliability.
Modafinil reliably sustains attention and reduces subjective sleepiness in sleep-deprived individuals. Evidence for broader cognitive enhancement in well-rested populations is not established.
The drug is approved for narcolepsy, obstructive sleep apnoea with residual sleepiness, and shift work sleep disorder. These indications share one feature: objectively measurable excessive daytime sleepiness.
Off-label use is widespread but the evidence does not support a general cognitive benefit. Some studies report task-specific improvements, while others find no advantage over placebo.
Modafinil binds the dopamine transporter and slows the reuptake of dopamine, so more remains available between neurons. This is weaker and slower than amphetamine-type stimulants, which also force dopamine release.
Animal work shows activation of orexin-producing neurons in the hypothalamus. Orexin helps stabilise the switch between sleep and wake states, which may explain the wake-promoting profile.
Downstream increases in histamine and norepinephrine activity have been reported in preclinical models. Both are involved in arousal and alertness.
No single mechanism fully explains modafinil’s effects, and translation from animal models to humans is incomplete. Descriptions here are simplified summaries, not settled fact.

Interest in modafinil has expanded beyond narcolepsy into cognitive enhancement, mood and neuroprotection. The evidence is mixed but growing.

Both compounds increase alertness through different pathways. Combining them can feel powerful, but the crash and anxiety risk rise too.

Most side effects are mild and dose dependent. A small number of users experience serious skin reactions that require immediate discontinuation.